title: The role of the immune system in the pathogenesis of cancer.
abstract: The observation that malignant cells express antigens that may be recognized by immunocytes and that immune effector mechanisms have the capability of destroying tumor cells has increased our appreciation of the biology of cancer and its relationship to immune function as well as offered new options for therapeutic intervention. Clinical trials are in progress to evaluate several different approaches to modifying the host's immune response against tumor. One approach is to administer agents that have direct activity against the malignancy. For example, antibody conjugates bring cytotoxic molecules of chemotherapy, radioisotopes, or toxins directly to the tumor. A second approach is to administer agents that modulate the host's own antitumor response such as IFN-alpha and IFN-gamma. Adoptive cellular immunotherapy aimed at isolating and expanding the host's own tumor-specific lymphocytes and inducing activation and proliferation with lymphokines such as IL-2 has shown encouraging results. Even though clinical data are still quite premature, it is reasonable to assume that in the future immunomodulation including the stimulation of immune effector mechanisms to eradicate tumor, the reconstitution of immune deficiency in diseases such as AIDS, the suppression of immune function to avoid graft rejection and GVHD, and the isolation and insertion of genes encoding tumor antigens into recombinant vectors to immunize the host to the tumor antigen will be commonly and successfully employed.
authors.affiliation: NeoRx Corporation, Seattle, WA 98119.
authors.forename: J W
authors.initials: JW
authors.lastname: Appelbaum
mesh_terms: D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology; D000957:Antigens, Viral, Tumor / Q000276:immunology; D001327:Autoimmune Diseases / Q000150:complications / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D015658:HIV Infections / Q000150:complications / Q000276:immunology; D015497:HIV-1; D006801:Humans; D007121:Immunocompetence; D016867:Immunocompromised Host; D051379:Mice; D009369:Neoplasms / Q000209:etiology / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000957:Antigens, Viral, Tumor